Cargando…
Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy
BACKGROUND: Indoleamine-2,3-dioxygenase 1 (IDO1) has been intensively pursued as a therapeutic target to reverse the immunosuppressive cancer-immune milieu and promote tumor elimination. However, recent failures of phase III clinical trials with IDO1 inhibitors involved in cancer immunotherapies hig...
Autores principales: | Xie, Lin, Hu, Kuan, Duo, Yanhong, Shimokawa, Takashi, Kumata, Katsushi, Zhang, Yiding, Jiang, Cuiping, Zhang, Lulu, Nengaki, Nobuki, Wakizaka, Hidekatsu, Cao, Yihai, Zhang, Ming-Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237741/ https://www.ncbi.nlm.nih.gov/pubmed/34148865 http://dx.doi.org/10.1136/jitc-2021-002616 |
Ejemplares similares
-
Synthesis of [(11)C]carbonyl-labeled cyclohexyl (5-(2-acetamidobenzo[d]thiazol-6-yl)-2-methylpyridin-3-yl)carbamate ([(11)C-carbonyl]PK68) as a potential PET tracer for receptor-interacting protein 1 kinase
por: Yamasaki, Tomoteru, et al.
Publicado: (2022) -
EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma
por: Bai, Hua, et al.
Publicado: (2020) -
Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target
por: Wang, Haizhou, et al.
Publicado: (2022) -
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures
por: Wei, Feifei, et al.
Publicado: (2023) -
GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape
por: Caforio, Matteo, et al.
Publicado: (2021)